ELAN
Neutral signalScored 2026-10-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Elanco Animal Health Incorporated
- Nom
- Elanco Animal Health Incorporated
- Secteur
- Healthcare
- Industrie
- Drug Manufacturers - Specialty & Generic
- Bourse
- NYSE
- Capitalisation
- $11.2B
- Employés
- 9,650
- PDG
- Jeffrey N. Simmons
- Site web
- https://www.elanco.com
- Marché
- IDXXMRKNEOGORINYPAHCZTS
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 55 000 titres (~1 281 870,00 $ US)
- Insiders
- Kurzius Lawrence ErikHarrington Michael JHerendeen Paul
- Total bought
-
$1,281,870
Avg buy (VWAP, 90d window) $23.31 vs last close $22.96 (-1.5%)
- Total sold
-
$100,050
Avg sell (VWAP, 90d window) $23.00 vs last close $22.96 (-0.2%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-20
- Liquidity
- Liquid $113,037,495/day · 20d vol
- Last synced
-
2026-10-26 21:10:25
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-15 | Bettington Timothy J | Sell · S | 4,350 | $23.00 | $100,050 | Form 4 |
| 2026-08-20 | Kurzius Lawrence Erik | Buy · P | 40,000 | $23.40 | $935,920 | Form 4 |
| 2026-08-18 | O'Neill Shiv | Buy · P | 3,998 | $23.58 | $94,273 | Form 4 |
| 2026-08-12 | Harrington Michael J | Buy · P | 5,000 | $21.82 | $109,100 | Form 4 |
| 2026-08-07 | Herendeen Paul | Buy · P | 10,000 | $23.68 | $236,850 | Form 4 |
| 2026-08-07 | VanHimbergen Robert M | Buy · P | 4,200 | $23.08 | $96,926 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-10-27 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-09-23 | Val Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2025-09-22 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-08-27 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-08-05 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-09-26 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-06-05 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-02-23 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-02-22 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-02-22 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-01-12 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-01-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-08-04 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-08-03 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-08-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-07-27 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-07-25 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2023-05-19 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-04-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-04-10 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-03-31 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-24 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-03-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-10 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-03-06 | Daniel Goldman | Sale (Partial) | $1,001 - $15,000 |
| 2023-03-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-02-24 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-02-22 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-02-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-02-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-01-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-01-05 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-30 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-28 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-27 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-22 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-16 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-15 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-07 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-30 | Susie Lee | Sale (Full) | $1,001 - $15,000 |
| 2022-11-30 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-22 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-16 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-11-15 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-15 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-02-17 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2021-06-21 | Susie Lee | Purchase | $1,001 - $15,000 |
| 2021-06-10 | Susie Lee | Purchase | $1,001 - $15,000 |
| 2020-12-21 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-11-06 | Susie Lee | Sale (Partial) | $1,001 - $15,000 |
| 2020-11-05 | Katherine M. Clark | Sale (Full) | $1,001 - $15,000 |
| 2020-10-22 | Katherine M. Clark | Purchase | $1,001 - $15,000 |
| 2020-06-16 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2019-12-27 | Susie Lee | Purchase | $1,001 - $15,000 |
| 2019-08-28 | Susie Lee | Purchase | $1,001 - $15,000 |
| 2019-08-20 | Alan Lowenthal | Sale (Full) | $15,001 - $50,000 |
| 2019-08-20 | Alan Lowenthal | Sale (Full) | $1,001 - $15,000 |
| 2019-04-25 | Susie Lee | Purchase | $1,001 - $15,000 |
| 2019-03-06 | Alan Lowenthal | Exchange | $1,001 - $15,000 |
| 2019-03-06 | Alan Lowenthal | Exchange | $1,001 - $15,000 |
| 2018-12-07 | Thomas Charles MacArthur | Sale (Full) | $15,001 - $50,000 |
| 2018-09-21 | Thomas Charles MacArthur | Purchase | $15,001 - $50,000 |
Signal
Neutral signalScored 2026-10-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
The insider cluster buy of $1.28M across 55k shares on 2026-08-20 provides a meaningful bullish signal, reinforced by named product launches (Quattro, Zenrelia) and stated deleveraging plans.
The first sentence of the analysis written for ELAN on 2026-10-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 2.17 · operating margin 5.3%
Suggested stop 22.41, nearest stored support minus 0.5 ATR(2.4% under the last close). Reward/risk to the next stored resistance is 2.68. Research, not advice. Not an order.
Recent news
- 2026-10-19 Will Elanco Animal Health (ELAN) Beat Estimates Again in Its Next Earnings Report? Elanco Animal Health (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 2026-09-26 Elanco Animal Health Eyes Growth, Deleveraging as Quattro and Zenrelia Gain Ground Elanco Animal Health NYSE: ELAN President and CEO Jeff Simmons outlined the company''s growth strategy, product launches, deleveraging plans and outlook for its pet health and farm animal businesses during the Bank of America Healthcare Conference in London.
- 2026-09-24 State Street Corp Has $395.31 Million Holdings in Elanco Animal Health Incorporated $ELAN State Street Corp grew its holdings in Elanco Animal Health Incorporated (NYSE: ELAN) by 4.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 16,063,046 shares of the company''s stock after purchasing an additional 726,567 shares during the quarter. State Street Corp owned
- 2026-09-22 Elanco Animal Health Incorporated (ELAN) Presents at Bank of America Global Healthcare Conference 2026 Transcript Elanco Animal Health Incorporated (ELAN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
- 2026-09-19 Analyzing Amarin (NASDAQ:AMRN) & Elanco Animal Health (NYSE:ELAN) Elanco Animal Health (NYSE: ELAN - Get Free Report) and Amarin (NASDAQ: AMRN - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings. Volatility and Risk Elanco Animal Health has a
- 2026-09-18 Elanco Animal Health Incorporated $ELAN Shares Acquired by Corient Private Wealth LP Corient Private Wealth LP lifted its position in shares of Elanco Animal Health Incorporated (NYSE: ELAN) by 124.1% during the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 342,271 shares of the company''s stock after buying an additional 189,540 shares during the period. Corient Private Wealth LP
- 2026-09-17 Elanco to Participate in BofA Securities Global Healthcare Conference 2026 INDIANAPOLIS, Sept. 17, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the BofA Securities Global Healthcare Conference 2026 on September 22, 2026.
- 2026-09-15 Elanco Animal Health Incorporated (ELAN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Elanco Animal Health Incorporated (ELAN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-15 Expanding Tick and Itch Season Supports Momentum in Elanco Innovation, Meeting Pet Owner Demand for Health and Wellness Care Innovation that protects against these pests is driving stronger Elanco base business and overall share gains. Elanco confirms U.S. Pet Health is on track to expectations of high-single digit to low double-digit growth in the second half of 2026.
- 2026-09-13 Squarepoint Ops LLC Purchases New Position in Elanco Animal Health Incorporated $ELAN Squarepoint Ops LLC acquired a new position in shares of Elanco Animal Health Incorporated (NYSE: ELAN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 133,225 shares of the company''s stock, valued at approximately $3,279,000. Several other institutional investors and hedge funds
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 43.5% | 43.0% | 43.9% | 44.7% | 43.6% | |
| Ebit Margin | -0.1% | 18.6% | -20.8% | 4.2% | -6.4% | |
| Ebitda Margin | 14.3% | 33.5% | -5.1% | 19.6% | 8.6% | |
| Operating Profit Margin | 5.3% | 5.7% | 7.4% | 8.7% | 6.4% | |
| Pretax Profit Margin | -4.8% | 11.0% | -27.1% | -1.6% | -12.0% | |
| Continuous Operations Profit Margin | -4.9% | 7.6% | -27.9% | -1.8% | -10.1% | |
| Net Profit Margin | -4.9% | 7.6% | -27.9% | -1.8% | -10.1% | |
| Bottom Line Profit Margin | -4.9% | 7.6% | -27.9% | -1.8% | -10.1% | |
| Current Ratio | 2.165 | 2.445 | 2.745 | 1.927 | 1.988 | |
| Quick Ratio | 1.078 | 1.248 | 1.347 | 1.023 | 1.155 | |
| Solvency Ratio | 0.066 | 0.153 | -0.066 | 0.074 | 0.026 | |
| Cash Ratio | 0.341 | 0.356 | 0.284 | 0.203 | 0.387 | |
| Price To Earnings Ratio | -48.149 | 17.809 | -5.960 | -81.467 | -29.258 | |
| Price To Earnings Growth Ratio | 0.285 | -0.140 | -0.004 | 0.964 | 1.239 | |
| Forward Price To Earnings Growth Ratio | 0.285 | -0.140 | -0.004 | 0.964 | 1.239 | |
| Price To Earnings Diluted Ratio | -48.149 | 17.809 | -5.960 | -81.467 | -29.258 | |
| Price To Earnings Diluted Growth Ratio | 0.285 | -0.140 | -0.004 | 0.964 | 1.239 | |
| Price To Book Ratio | 1.716 | 0.981 | 1.179 | 0.819 | 1.842 | |
| Price To Sales Ratio | 2.383 | 1.348 | 1.661 | 1.353 | 2.902 | |
| Price To Free Cash Flow Ratio | 39.555 | 15.184 | 62.695 | 22.265 | 48.345 | |
| Price To Operating Cash Flow Ratio | 20.060 | 11.058 | 27.067 | 13.201 | 28.627 | |
| Debt To Assets Ratio | 0.301 | 0.343 | 0.402 | 0.377 | 0.383 | |
| Debt To Equity Ratio | 0.614 | 0.709 | 0.928 | 0.801 | 0.842 | |
| Debt To Capital Ratio | 0.380 | 0.415 | 0.481 | 0.445 | 0.457 | |
| Long Term Debt To Capital Ratio | 0.376 | 0.412 | 0.480 | 0.428 | 0.445 | |
| Financial Leverage Ratio | 2.040 | 2.069 | 2.308 | 2.125 | 2.195 | |
| Working Capital Turnover Ratio | 2.507 | 2.183 | 2.360 | 2.753 | 3.211 | |
| Operating Cash Flow Ratio | 0.351 | 0.411 | 0.218 | 0.266 | 0.293 | |
| Operating Cash Flow Sales Ratio | 0.119 | 0.122 | 0.061 | 0.102 | 0.101 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.507 | 0.728 | 0.432 | 0.593 | 0.592 | |
| Debt Service Coverage Ratio | 2.272 | 3.496 | -0.825 | 1.335 | 0.891 | |
| Interest Coverage Ratio | 1.145 | 0.740 | 1.177 | 1.500 | 1.152 | |
| Short Term Operating Cash Flow Coverage Ratio | 7.568 | 12.295 | 7.132 | 1.165 | 1.643 | |
| Operating Cash Flow Coverage Ratio | 0.139 | 0.125 | 0.047 | 0.077 | 0.076 | |
| Capital Expenditure Coverage Ratio | 2.029 | 3.680 | 1.760 | 2.457 | 2.452 | |
| Dividend Paid And Capex Coverage Ratio | 2.029 | 3.680 | 1.760 | 2.457 | 2.452 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 21.754 | 6.605 | -56.952 | 13.231 | 47.696 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 43.5% | ▲0.5% | ▼-0.2% |
| Ebit Margin | -0.1% | ▼-18.7% | ▲0.8% |
| Ebitda Margin | 14.3% | ▼-19.2% | ▲0.1% |
| Operating Profit Margin | 5.3% | ▼-0.3% | ▼-1.4% |
| Pretax Profit Margin | -4.8% | ▼-15.7% | ▲2.1% |
| Continuous Operations Profit Margin | -4.9% | ▼-12.5% | ▲2.5% |
| Net Profit Margin | -4.9% | ▼-12.5% | ▲2.5% |
| Bottom Line Profit Margin | -4.9% | ▼-12.5% | ▲2.5% |
| Current Ratio | 2.165 | ▼-0.280 | ▼-0.089 |
| Quick Ratio | 1.078 | ▼-0.170 | ▼-0.093 |
| Solvency Ratio | 0.066 | ▼-0.088 | ▲0.015 |
| Cash Ratio | 0.341 | ▼-0.015 | ▲0.027 |
| Price To Earnings Ratio | -48.149 | ▼-65.958 | ▼-18.744 |
| Price To Earnings Growth Ratio | 0.285 | ▲0.425 | ▼-0.184 |
| Forward Price To Earnings Growth Ratio | 0.285 | ▲0.425 | ▼-0.184 |
| Price To Earnings Diluted Ratio | -48.149 | ▼-65.958 | ▼-18.744 |
| Price To Earnings Diluted Growth Ratio | 0.285 | ▲0.425 | ▼-0.184 |
| Price To Book Ratio | 1.716 | ▲0.735 | ▲0.409 |
| Price To Sales Ratio | 2.382 | ▲1.035 | ▲0.453 |
| Price To Free Cash Flow Ratio | 39.555 | ▲24.371 | ▲1.946 |
| Price To Operating Cash Flow Ratio | 20.060 | ▲9.002 | ▲0.057 |
| Debt To Assets Ratio | 0.301 | ▼-0.042 | ▼-0.060 |
| Debt To Equity Ratio | 0.614 | ▼-0.095 | ▼-0.165 |
| Debt To Capital Ratio | 0.380 | ▼-0.035 | ▼-0.055 |
| Long Term Debt To Capital Ratio | 0.376 | ▼-0.036 | ▼-0.052 |
| Financial Leverage Ratio | 2.040 | ▼-0.029 | ▼-0.107 |
| Working Capital Turnover Ratio | 2.507 | ▲0.324 | ▼-0.096 |
| Operating Cash Flow Ratio | 0.351 | ▼-0.061 | ▲0.043 |
| Operating Cash Flow Sales Ratio | 0.119 | ▼-0.003 | ▲0.018 |
| Free Cash Flow Operating Cash Flow Ratio | 0.507 | ▼-0.221 | ▼-0.063 |
| Debt Service Coverage Ratio | 2.272 | ▼-1.224 | ▲0.838 |
| Interest Coverage Ratio | 1.145 | ▲0.405 | ▲0.003 |
| Short Term Operating Cash Flow Coverage Ratio | 7.568 | ▼-4.728 | ▲1.607 |
| Operating Cash Flow Coverage Ratio | 0.139 | ▲0.014 | ▲0.046 |
| Capital Expenditure Coverage Ratio | 2.029 | ▼-1.651 | ▼-0.447 |
| Dividend Paid And Capex Coverage Ratio | 2.029 | ▼-1.651 | ▼-0.447 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 21.754 | ▲15.148 | ▲15.287 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $11.23B | $5.98B | $7.34B | $5.97B | $13.83B | |
| Enterprise value | $14.71B | $9.84B | $12.76B | $11.46B | $19.51B | |
| EV / Sales | 3.12x | 2.22x | 2.89x | 2.60x | 4.09x | |
| EV / Op. cash flow | 26.26x | 18.18x | 47.08x | 25.35x | 40.39x | |
| EV / Free cash flow | 51.78x | 24.96x | 109.04x | 42.75x | 68.21x | |
| EV / EBITDA | 21.75x | 6.61x | -56.95x | 13.23x | 47.70x | |
| Net debt / EBITDA | 5.14x | 2.59x | -24.20x | 6.34x | 13.89x | |
| Current ratio | 2.17x | 2.44x | 2.75x | 1.93x | 1.99x | |
| Income quality | -2.41x | 1.60x | -0.22x | -5.79x | -1.02x | |
| Graham number | — | $14 | — | — | — | |
| Graham net-net | -$9 | -$9 | -$13 | -$13 | -$14 | |
| Tax burden | 103.6% | 69.3% | 103.0% | 108.3% | 84.6% | |
| Interest burden | 5600.0% | 59.0% | 130.2% | -39.1% | 186.0% | |
| Working capital | $1.86B | $1.90B | $2.17B | $1.58B | $1.63B | |
| Invested capital | $11.46B | $10.99B | $12.78B | $13.41B | $14.44B | |
| Return on assets | -1.7% | 2.7% | -8.6% | -0.5% | -2.9% | |
| Operating ROA | 1.9% | 1.9% | 2.2% | 2.4% | 1.8% | |
| Return on tangible assets | -4.5% | 7.5% | -25.8% | -1.7% | -10.2% | |
| Return on equity | -3.5% | 5.5% | -19.8% | -1.1% | -6.4% | |
| Return on invested capital | 2.1% | 1.5% | 2.5% | 2.7% | 1.7% | |
| Return on capital employed | 2.1% | 2.2% | 2.5% | 2.8% | 2.0% | |
| Earnings yield | -2.1% | 5.6% | -16.8% | -1.3% | -3.5% | |
| Free cash flow yield | 2.5% | 6.6% | 1.6% | 4.5% | 2.1% | |
| Capex / Op. cash flow | 49.3% | 27.2% | 56.8% | 40.7% | 40.8% | |
| Capex / Depreciation | 40.6% | 22.2% | 22.2% | 27.0% | 27.5% | |
| Capex / Sales | 5.9% | 3.3% | 3.5% | 4.2% | 4.1% | |
| SG&A / Sales | 30.3% | 29.6% | 29.1% | 28.7% | 29.5% | |
| R&D / Sales | 7.8% | 7.7% | 7.4% | 7.3% | 7.7% | |
| Stock comp / Sales | 1.4% | 1.2% | 1.0% | 1.3% | 1.4% | |
| Intangibles / Total assets | 61.3% | 64.2% | 66.8% | 69.9% | 71.4% | |
| Days sales outstanding | 73d | 73d | 83d | 83d | 79d | |
| Days payables outstanding | 50d | 43d | 40d | 58d | 56d | |
| Operating cycle | 311d | 300d | 339d | 313d | 265d | |
| Cash conversion cycle | 260d | 257d | 299d | 255d | 208d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years